MX340098B - Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos. - Google Patents

Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos.

Info

Publication number
MX340098B
MX340098B MX2013007661A MX2013007661A MX340098B MX 340098 B MX340098 B MX 340098B MX 2013007661 A MX2013007661 A MX 2013007661A MX 2013007661 A MX2013007661 A MX 2013007661A MX 340098 B MX340098 B MX 340098B
Authority
MX
Mexico
Prior art keywords
phenyl
preparation process
isoxazol
derivatives
compound
Prior art date
Application number
MX2013007661A
Other languages
English (en)
Other versions
MX2013007661A (es
Inventor
Dong Yeon Kim
Dae Jin Cho
Gong Yeal Lee
Hong Youb Kim
Seok Hun Woo
Hae Un Lee
Sung Moo Kim
Chong Am Ahn
Original Assignee
Il-Yang Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46514985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX340098(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Il-Yang Pharm Co Ltd filed Critical Il-Yang Pharm Co Ltd
Publication of MX2013007661A publication Critical patent/MX2013007661A/es
Publication of MX340098B publication Critical patent/MX340098B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe un compuesto derivado de fenil-isoxazol representado por la Fórmula 1 que se describe a continuación, que es útil como material de tratamiento para infecciones virales, especialmente la infección causada por un virus de la influenza, o su derivado farmacéuticamente aceptable, un método de preparación del mismo y una composición farmacéutica para el tratamiento de enfermedades, incluyendo el compuesto como principio activo:Fórmula 1 (Ver Formula) donde en la Fórmula citada anteriormente, R1, R2, R3, R4 y R8 son iguales a los que se define en la especificación.
MX2013007661A 2011-04-19 2012-03-30 Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos. MX340098B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110036172A KR101369584B1 (ko) 2011-04-19 2011-04-19 페닐-이속사졸 유도체 및 그의 제조방법
PCT/KR2012/002362 WO2012144752A1 (en) 2011-04-19 2012-03-30 Phenyl-isoxazol derivatives and preparation process thereof

Publications (2)

Publication Number Publication Date
MX2013007661A MX2013007661A (es) 2013-08-12
MX340098B true MX340098B (es) 2016-06-27

Family

ID=46514985

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007661A MX340098B (es) 2011-04-19 2012-03-30 Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos.

Country Status (21)

Country Link
US (1) US9132126B2 (es)
EP (1) EP2699566B1 (es)
JP (1) JP5833143B2 (es)
KR (1) KR101369584B1 (es)
CN (1) CN103313982B (es)
AR (1) AR086029A1 (es)
AU (1) AU2012246914B2 (es)
CA (1) CA2824757A1 (es)
CL (1) CL2013001910A1 (es)
CO (1) CO6771432A2 (es)
EA (1) EA022336B1 (es)
HK (1) HK1188998A1 (es)
IL (1) IL227711A0 (es)
MX (1) MX340098B (es)
PE (1) PE20140629A1 (es)
SA (1) SA112330457B1 (es)
SG (1) SG192134A1 (es)
TW (1) TWI434836B (es)
UY (1) UY34023A (es)
WO (1) WO2012144752A1 (es)
ZA (1) ZA201305277B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018141854A1 (en) 2017-02-02 2018-08-09 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibition
AU2018216954B2 (en) 2017-02-02 2022-04-14 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibition
MX2019009443A (es) * 2017-02-08 2019-12-16 Biotron Ltd Metodos para tratar la influenza.
TWI765323B (zh) * 2019-08-22 2022-05-21 大陸商四川海思科製藥有限公司 抗流感病毒化合物及其製備方法和用途
CN111704587B (zh) * 2020-06-29 2023-04-07 遵义医科大学 一种三氟甲基化1,3-噁嗪类化合物的合成方法
CN114349746A (zh) * 2020-11-19 2022-04-15 中国医学科学院医药生物技术研究所 一种含有4-氟苯基片段的吡啶类化合物及其制备方法和应用、药物组合物
WO2022166767A1 (zh) 2021-02-04 2022-08-11 四川海思科制药有限公司 Ha抑制剂化合物的盐及晶型

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8427618D0 (en) * 1984-11-01 1984-12-05 Shell Int Research Anticoccidial compositions
SK282950B6 (sk) 1990-04-24 2003-01-09 Biota Scientific Management Pty Ltd Deriváty alfa-D-neuramínovej kyseliny, spôsob ich prípravy, ich použitie a farmaceutické prípravky na ich báze
BR9607098B8 (pt) 1995-02-27 2014-11-18 Gilead Sciences Inc Composto e composição farmacêutica.
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
ES2180456B1 (es) * 2001-07-20 2004-05-01 Laboratorios S.A.L.V.A.T., S.A. Isoxazoles sustituidos y su utilizacion como antibioticos.
US6809204B2 (en) 2001-10-12 2004-10-26 Onconova Therapeutics, Inc. Processes for the preparation of substituted isoxazoles and 2-isoxazolines
AU2003246571B2 (en) * 2002-06-29 2008-06-26 Zentaris Gmbh Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases
AU2003232650A1 (en) 2003-05-06 2004-11-26 Il Yang Pharm Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
KR20050051729A (ko) 2003-11-28 2005-06-02 일양약품주식회사 사이클로 옥시게나제-2 억제제인 페닐 헤테로사이클의제조방법
CN1687075A (zh) * 2005-03-24 2005-10-26 天津药物研究院 3-苯基异噁唑-5-甲酰胺基取代β-内酰胺类衍生物及其用途
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
KR100674813B1 (ko) 2005-08-05 2007-01-29 일양약품주식회사 N-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
CA2659155A1 (en) * 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11.beta.-hsd-1
WO2009084024A2 (en) 2007-11-02 2009-07-09 Glenmark Generics Limited A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
US20090192326A1 (en) 2007-11-13 2009-07-30 Nurit Perlman Preparation of sitagliptin intermediate
JP2011507910A (ja) * 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
KR101044880B1 (ko) 2008-06-12 2011-06-28 일양약품주식회사 항궤양제 화합물의 합성에 유용한 중간체의 제조방법
KR20100021321A (ko) 2008-08-14 2010-02-24 일양약품주식회사 Ν-페닐-2-피리미딘-아민 유도체의 제조방법
WO2010135520A1 (en) * 2009-05-20 2010-11-25 Chimerix, Inc. Compounds, compositions and methods for treating viral infection
EP2462138B1 (en) * 2009-08-05 2014-09-24 Versitech Limited Antiviral compounds and methods of making
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
ES2533068T3 (es) 2010-09-08 2015-04-07 Bristol-Myers Squibb Company Nuevos análogos de piperazina como antivirales de influenza de amplio espectro
WO2012044531A1 (en) 2010-09-28 2012-04-05 Bristol-Myers Squibb Company Novel piperazine analogs with substituted heteroaryl groups as broad-spectrum influenza antivirals
KR101956586B1 (ko) 2012-03-27 2019-03-11 일양약품주식회사 약제학적 조성물 및 이의 제조방법

Also Published As

Publication number Publication date
CO6771432A2 (es) 2013-10-15
IL227711A0 (en) 2013-09-30
CL2013001910A1 (es) 2014-04-21
CN103313982A (zh) 2013-09-18
US20140031364A1 (en) 2014-01-30
EP2699566A4 (en) 2014-09-03
EA201300805A1 (ru) 2013-11-29
TWI434836B (zh) 2014-04-21
AU2012246914B2 (en) 2015-09-24
TW201309658A (zh) 2013-03-01
NZ613314A (en) 2015-09-25
US9132126B2 (en) 2015-09-15
CN103313982B (zh) 2016-02-03
ZA201305277B (en) 2014-09-25
EP2699566A1 (en) 2014-02-26
HK1188998A1 (zh) 2014-05-23
CA2824757A1 (en) 2012-10-26
MX2013007661A (es) 2013-08-12
JP5833143B2 (ja) 2015-12-16
WO2012144752A1 (en) 2012-10-26
KR101369584B1 (ko) 2014-03-06
KR20120118665A (ko) 2012-10-29
AR086029A1 (es) 2013-11-13
UY34023A (es) 2012-06-29
SA112330457B1 (ar) 2015-08-19
JP2014503601A (ja) 2014-02-13
PE20140629A1 (es) 2014-05-22
EP2699566B1 (en) 2017-02-22
EA022336B1 (ru) 2015-12-30
SG192134A1 (en) 2013-08-30
AU2012246914A1 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
GEP20156263B (en) Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for production and usage thereof
ZA201608614B (en) Solid oral pharmaceutical compositions for isoxazoline compounds
MX340098B (es) Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos.
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
MD4602B1 (ro) Inhibitori ai virusului hepatic C
GEP201606531B (en) Inhibitors of influenza viruses replication
MD20150092A2 (ro) Derivate ale amidelor pentru tratamentul infecţiei cu HIV
MD20140063A2 (ro) Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
HK1166788A1 (es)
EA201270800A1 (ru) С-28 амиды модифицированных производных с-3 бетулиновой кислоты в качестве ингибиторов созревания вич
EA201391127A1 (ru) C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201270780A1 (ru) С-3 модифицированные производные бетулиновой кислоты в качестве ингибиторов созревания вич
PH12016502103A1 (en) Novel disubstituted 1,2, 4-triazine compound
SG179082A1 (en) Method for the preparation of an influenza virus
IN2012DN01855A (es)
EA025518B9 (ru) Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств
MX350746B (es) Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral.
EP2722042A4 (en) INDANONE DERIVATIVES, THEIR OPTICAL ISOMERS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2011097946A8 (zh) 含有并环稠合双环的噁唑烷酮化合物及其制备和应用
EP2796450A4 (en) 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES
EP2583969A4 (en) NEW RHODANINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS WITH THE RHODANIN DERIVATIVES AS ACTIVE AGENTS
BR112015010271A8 (pt) produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
UA105285C2 (uk) Тверда фармацевтична композиція раміприлу і безилату амлодипіну і її отримання

Legal Events

Date Code Title Description
FG Grant or registration